Rep Name|Suggested Channel|HCP Priority Trend for Ocrevus|Adjusted Expected Value|Aktana HCP Value|Suggestion Reason|HCP Name|Is Suggestion Recommended|Facility Address|HCP Speciality|Is Visit Channel Propensity High|source|Product switch from|Product switch to|New prescriber|Repeat prescriber|Suggestion Date
Direm Nimir|SEND|Increase|High|Low|Our data indicates that Nered Samir has MS diagnosed patients at UCHEALTH UNIVERSITY OF COLORADO HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Nered Samir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nered Samir|FALSE|12631 E 17th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-27
Direm Nimir|SEND|Increase|High|Low|Our data indicates that Nered Samir has MS diagnosed patients at UCHEALTH UNIVERSITY OF COLORADO HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Nered Samir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nered Samir|TRUE|12631 E 17th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-29
Direm Nimir|SEND|Increase|Medium|Low|Our data indicates that Kamil Bason has MS diagnosed patients at RENOWN REGIONAL MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Kamil Bason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kamil Bason|FALSE|Global|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-17
Direm Nimir|SEND|Increase|Medium|Low|Our data indicates that Sanak Kodan has MS diagnosed patients at ROCKY MOUNTAIN MULTIPLE SCLEROSIS CLINIC that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Sanak Kodan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Sanak Kodan|FALSE|370 E 9th Ave|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-27
Direm Nimir|SEND|Increase|Medium|Low|Our data indicates that Zakit Fison has MS diagnosed patients at CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|FALSE|Global|NEUROLOGY|FALSE|suggestions|||||2023-01-27
Direm Nimir|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|FALSE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions||||MAVENCLAD|2023-01-29
Direm Nimir|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions||||MAVENCLAD|2023-01-22
Direm Nimir|SEND|Missing|Medium|Low|Our data indicates that Miver Lenos has MS diagnosed patients at SWEDISH MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Miver Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Miver Lenos|FALSE|Global|NEUROLOGY|TRUE|suggestions|||||2023-01-29
Direm Nimir|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Renat Komel has switched 1.0 patients from OCREVUS to TYSABRI.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Renat Komel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Renat Komel|TRUE|4251 Kipling St|NEUROLOGY,NEUROMUSCULAR MEDICINE,PHYSICAL MEDICINE AND REHABILITATION|TRUE|suggestions|OCREVUS|TYSABRI|||2023-01-29
Direm Nimir|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Renat Komel has switched 1.0 patients from OCREVUS to VUMERITY.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Renat Komel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Renat Komel|TRUE|4251 Kipling St|NEUROLOGY,NEUROMUSCULAR MEDICINE,PHYSICAL MEDICINE AND REHABILITATION|TRUE|suggestions|OCREVUS|VUMERITY|||2023-01-30
Direm Nimir|VISIT|Decline|Medium|Low|For the three months ending in (September, 2023), Savel Fitek has switched 1.0 patients from OCREVUS to BRIUMVI.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Savel Fitek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Savel Fitek|FALSE|Global|NEUROLOGY|TRUE|suggestions|OCREVUS|BRIUMVI|||2023-01-16
Direm Nimir|VISIT|Hold|Medium|Low|For the three months ending in (September, 2023), Revem Satek has switched 1.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Revem Satek is a(n) Ray. N/ADr. Revem Satek received their last Enspryng sample more than 2 months ago but we don’t see an order from Dr. Revem Satek in the most recent sales data. Please follow up with HCP to understand their experience with the sampling program, using the sample, or explore reasons if they have not placed an order yet.|Revem Satek|TRUE|1619 N Greenwood St|VASCULAR NEUROLOGY,NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-16
Direm Nimir|VISIT|Increase|High|Low|Our data indicates that Sanak Kodan has MS diagnosed patients at ROCKY MOUNTAIN MULTIPLE SCLEROSIS CLINIC that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Sanak Kodan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Sanak Kodan|FALSE|Global|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-27
Direm Nimir|VISIT|Increase|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with CHRISTEN FISCELLA KUTZ. Please evaluate using your own judgement and consider reaching out to CHRISTEN FISCELLA KUTZ.Dr. Miret Tumel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Miret Tumel|FALSE|2312 N Nevada Ave|NEUROLOGY,GENERAL PRACTICE,GENERAL SURGERY|FALSE|suggestions|||||2023-01-16
Direm Nimir|VISIT|Increase|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with CHRISTEN FISCELLA KUTZ. Please evaluate using your own judgement and consider reaching out to CHRISTEN FISCELLA KUTZ.Dr. Miret Tumel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Miret Tumel|TRUE|2312 N Nevada Ave|NEUROLOGY,GENERAL PRACTICE,GENERAL SURGERY|FALSE|suggestions|||||2023-01-17
Direm Nimir|VISIT|Increase|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with TRACIE ANNE CALLER. Please evaluate using your own judgement and consider reaching out to TRACIE ANNE CALLER.Dr. Mitat Kovak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Mitat Kovak|TRUE|2301 House Ave|NEUROLOGY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-29
Direm Nimir|VISIT|Increase|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with ROBERT HARRIS GROSS. Please evaluate using your own judgement and consider reaching out to ROBERT HARRIS GROSS.Dr. Nerer Hamir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nerer Hamir|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-29
Direm Nimir|VISIT|Increase|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with ROBERT HARRIS GROSS. Please evaluate using your own judgement and consider reaching out to ROBERT HARRIS GROSS.Dr. Nerer Hamir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nerer Hamir|TRUE|12631 E 17th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Turek Bamel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Turek Bamel|FALSE|2695 Rocky Mountain Ave|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|TRUE|suggestions|||KESIMPTA||2023-01-16
Direm Nimir|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Turek Bamel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Turek Bamel|TRUE|2695 Rocky Mountain Ave|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|TRUE|suggestions|||KESIMPTA||2023-01-17
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Redot Ledan has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Redot Ledan is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Redot Ledan|TRUE|888 W Bonneville Ave|FAMILY MEDICINE,GENERAL PRACTICE,NEUROLOGY|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-19
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Redot Ledan has switched 2.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Redot Ledan is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Redot Ledan|TRUE|888 W Bonneville Ave|FAMILY MEDICINE,GENERAL PRACTICE,NEUROLOGY|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-18
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Revem Satek has switched 1.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Revem Satek is a(n) Ray. N/ADr. Revem Satek received their last Enspryng sample more than 2 months ago but we don’t see an order from Dr. Revem Satek in the most recent sales data. Please follow up with HCP to understand their experience with the sampling program, using the sample, or explore reasons if they have not placed an order yet.|Revem Satek|TRUE|1619 N Greenwood St|VASCULAR NEUROLOGY,NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-19
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Revem Satek has switched 4.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Revem Satek is a(n) Ray. N/ADr. Revem Satek received their last Enspryng sample more than 2 months ago but we don’t see an order from Dr. Revem Satek in the most recent sales data. Please follow up with HCP to understand their experience with the sampling program, using the sample, or explore reasons if they have not placed an order yet.|Revem Satek|FALSE|Global|VASCULAR NEUROLOGY,NEUROLOGY|FALSE|suggestions|OCREVUS|KESIMPTA|||2023-01-18
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Saver Samel has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Saver Samel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Saver Samel|FALSE|9280 W Sunset Rd|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-29
Direm Nimir|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Saver Samel has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Saver Samel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Saver Samel|TRUE|9280 W Sunset Rd|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-27
Direm Nimir|VISIT|Missing|High|Low|Our data indicates that Tudor Kotek has MS diagnosed patients at SAINT ANTHONY HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Tudor Kotek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudor Kotek|FALSE|Global|GENERAL PRACTICE|TRUE|suggestions|||||2023-01-18
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with ANNA AJAY SHAH. Please evaluate using your own judgement and consider reaching out to ANNA AJAY SHAH.Dr. Nesat Konos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nesat Konos|TRUE|12700 E 19th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with KIMBERLY LUE WAGNER. Please evaluate using your own judgement and consider reaching out to KIMBERLY LUE WAGNER.Dr. Fakil Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fakil Konos|FALSE|2312 N Nevada Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with KIMBERLY LUE WAGNER. Please evaluate using your own judgement and consider reaching out to KIMBERLY LUE WAGNER.Dr. Fakil Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fakil Konos|TRUE|2312 N Nevada Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-20
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with Nered Samir ALVAREZ. Please evaluate using your own judgement and consider reaching out to Nered Samir ALVAREZ.Dr. Nered Samir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nered Samir|FALSE|12631 E 17th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-18
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with Nered Samir ALVAREZ. Please evaluate using your own judgement and consider reaching out to Nered Samir ALVAREZ.Dr. Nered Samir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nered Samir|TRUE|12631 E 17th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in October, is/are not known to be on Ocrevus, and is/are associated with JULIE BAAK SEIBERT. Please evaluate using your own judgement and consider reaching out to JULIE BAAK SEIBERT.Dr. Sanam Nitek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Sanam Nitek|TRUE|4 W Dry Creek Cir|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|High|Medium|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with AUGUSTO ALBERTO MIRAVALLE. Please evaluate using your own judgement and consider reaching out to AUGUSTO ALBERTO MIRAVALLE.Dr. Dinat Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dinat Sason|FALSE|12700 E 19th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|High|Medium|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with AUGUSTO ALBERTO MIRAVALLE. Please evaluate using your own judgement and consider reaching out to AUGUSTO ALBERTO MIRAVALLE.Dr. Dinat Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dinat Sason|TRUE|12700 E 19th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-21
Direm Nimir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Fakin Kovak has switched 1.0 patients from VUMERITY to OCREVUS.Consider a follow-up action based on your discretion.Dr. Fakin Kovak is a(n) Unknown. N/A|Fakin Kovak|FALSE|Global|NEUROLOGY,GENERAL PRACTICE|TRUE|suggestions|VUMERITY|OCREVUS|||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Fakin Kovak has switched 2.0 patients from VUMERITY to OCREVUS.Consider a follow-up action based on your discretion.Dr. Fakin Kovak is a(n) Unknown. N/A|Fakin Kovak|FALSE|Global|NEUROLOGY,GENERAL PRACTICE|TRUE|suggestions|VUMERITY|OCREVUS|||2023-01-18
Direm Nimir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Nerer Hamir has switched 1.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Nerer Hamir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nerer Hamir|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|KESIMPTA|||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Nerer Hamir has switched 2.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Nerer Hamir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Nerer Hamir|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|KESIMPTA|||2023-01-18
Direm Nimir|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Fakin Kovak has switched 1.0 patients from VUMERITY to OCREVUS.Consider a follow-up action based on your discretion.Dr. Fakin Kovak is a(n) Unknown. N/A|Fakin Kovak|TRUE|1925 Mountain View Ave|NEUROLOGY,GENERAL PRACTICE|TRUE|suggestions|VUMERITY|OCREVUS|||2023-01-16
Direm Nimir|VISIT|Missing|Medium|Low|Our data indicates that Losas Dotek has MS diagnosed patients at MEMORIAL HOSPITAL OF LARAMIE COUNTY that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Losas Dotek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Losas Dotek|TRUE|2003 Bluegrass Cir|NEUROLOGY,CHILD NEUROLOGY,NEUROLGY/DIAGNSTC RADIOLGY/NEURORADIOLGY|TRUE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|Our data indicates that Miver Lenos has MS diagnosed patients at SWEDISH MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Miver Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Miver Lenos|TRUE|701 E Hampden Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-29
Direm Nimir|VISIT|Missing|Medium|Low|There has been an unusual decrease in sales volume of 5.0 at this account Sasat Finos of CENTENNIAL for Ocrevus between 2023-07-18 and 2023-10-16. Please evaluate using your own judgment and any other approved internal tools (i.e. Priority Account Tool, Core Sales Aid, etc.) that you have available.We believe the unusual activity could be driven by the following:1) Corp Sales Increase2) Sales market share of Tysabri increased3) Sales market share of Ocrevus decreased|Sasat Finos|FALSE|7307 S Revere Pkwy|GENERAL PRACTICE|FALSE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|Medium|Low|There has been an unusual decrease in sales volume of 5.0 at this account Sasat Finos of CENTENNIAL for Ocrevus between 2023-07-18 and 2023-10-16. Please evaluate using your own judgment and any other approved internal tools (i.e. Priority Account Tool, Core Sales Aid, etc.) that you have available.We believe the unusual activity could be driven by the following:1) Corp Sales Increase2) Sales market share of Tysabri increased3) Sales market share of Ocrevus decreased|Sasat Finos|TRUE|7307 S Revere Pkwy|GENERAL PRACTICE|FALSE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with PATRICK JOHN BUSHARD. Please evaluate using your own judgement and consider reaching out to PATRICK JOHN BUSHARD.Dr. Nerer Leson is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Nerer Leson|FALSE|Global|GENERAL PRACTICE|FALSE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with TERI LEE SCHREINER. Please evaluate using your own judgement and consider reaching out to TERI LEE SCHREINER.Dr. Lotal Finos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Lotal Finos|FALSE|13123 E 16th Ave|CHILD NEUROLOGY,NEUROLOGY,PEDIATRICS|FALSE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with TERI LEE SCHREINER. Please evaluate using your own judgement and consider reaching out to TERI LEE SCHREINER.Dr. Lotal Finos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Lotal Finos|TRUE|13123 E 16th Ave|CHILD NEUROLOGY,NEUROLOGY,PEDIATRICS|FALSE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in May, is/are not known to be on Ocrevus, and is/are associated with ANGELO MARIO SANTIAGO. Please evaluate using your own judgement and consider reaching out to ANGELO MARIO SANTIAGO.Dr. Kasak Finos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kasak Finos|FALSE|5820 E 2nd St|NEUROLOGY|FALSE|suggestions|||||2023-01-20
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in May, is/are not known to be on Ocrevus, and is/are associated with ANGELO MARIO SANTIAGO. Please evaluate using your own judgement and consider reaching out to ANGELO MARIO SANTIAGO.Dr. Kasak Finos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kasak Finos|TRUE|5820 E 2nd St|NEUROLOGY|FALSE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in May, is/are not known to be on Ocrevus, and is/are associated with WILLIAM RICHARD SHAFFER. Please evaluate using your own judgement and consider reaching out to WILLIAM RICHARD SHAFFER.Dr. Lokik Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Lokik Lenos|FALSE|2315 E Harmony Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-19
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in May, is/are not known to be on Ocrevus, and is/are associated with WILLIAM RICHARD SHAFFER. Please evaluate using your own judgement and consider reaching out to WILLIAM RICHARD SHAFFER.Dr. Lokik Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Lokik Lenos|TRUE|2315 E Harmony Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in October, is/are not known to be on Ocrevus, and is/are associated with JEFFREY WILLIAM GROVES. Please evaluate using your own judgement and consider reaching out to JEFFREY WILLIAM GROVES.Dr. Mivem Dotek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Mivem Dotek|FALSE|Global|GENERAL PRACTICE|TRUE|suggestions|||||2023-01-22
Direm Nimir|VISIT|Missing|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Zadol Tumir is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Zadol Tumir|TRUE|A015f00000vbkbv|NEUROLOGY|FALSE|suggestions|||KESIMPTA||2023-01-16
Disak Domel|SEND|Hold|High|Low|Our data indicates that Midos Samel has MS diagnosed patients at SAINT CHARLES HEALTH SYSTEM that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Midos Samel is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Midos Samel|TRUE|2349 Ne Conners Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-28
Disak Domel|SEND|Increase|High|Low|Our data indicates that Minat Dovak has MS diagnosed patients at MCKENZIE WILLAMETTE MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Minat Dovak is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Minat Dovak|TRUE|3355 Riverbend Dr|NEUROLOGY|TRUE|suggestions|||||2023-01-21
Disak Domel|SEND|Increase|High|Medium|Our data indicates that Fakit Nimir has MS diagnosed patients at OREGON HEALTH AND SCIENCE UNIVERSITY HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Fakit Nimir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fakit Nimir|TRUE|3303 S Bond Ave|NEUROLOGY|FALSE|suggestions|||||2023-01-21
Disak Domel|SEND|Increase|High|Medium|Our data indicates that Satam Fidan has MS diagnosed patients at OREGON HEALTH AND SCIENCE UNIVERSITY HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Satam Fidan is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Satam Fidan|TRUE|3181 Sw Sam Jackson Park Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-29
Disak Domel|SEND|Increase|High|Medium|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Satam Fidan is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Satam Fidan|TRUE|3181 Sw Sam Jackson Park Rd|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-21
Disak Domel|SEND|Missing|High|High|Our data indicates that Satam Fidan has MS diagnosed patients at OREGON HEALTH AND SCIENCE UNIVERSITY HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Satam Fidan is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Satam Fidan|TRUE|3181 Sw Sam Jackson Park Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-15
Disak Domel|SEND|Missing|High|Medium|Our data indicates that Midos Samel has MS diagnosed patients at SAINT CHARLES HEALTH SYSTEM that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Midos Samel is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Midos Samel|TRUE|2349 Ne Conners Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-15
Disak Domel|VISIT|Hold|High|Low|For the three months ending in (September, 2023), Saret Domir has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Saret Domir is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Saret Domir|TRUE|9135 Sw Barnes Rd|NEUROLOGY|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-17
Disak Domel|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in March, is/are not known to be on Ocrevus, and is/are associated with JOSE ILDEFONSO RODRIGUEZ MORENO. Please evaluate using your own judgement and consider reaching out to JOSE ILDEFONSO RODRIGUEZ MORENO.Dr. Midom Koson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Midom Koson|TRUE|2900 State St|NEUROLOGY,CHILD NEUROLOGY|FALSE|suggestions|||||2023-01-22
Disak Domel|VISIT|Missing|High|Medium|There was/were 1 patient(s) who visited Ocreuvs.com in March, is/are not known to be on Ocrevus, and is/are associated with WALTER GINO CARLINI. Please evaluate using your own judgement and consider reaching out to WALTER GINO CARLINI.Dr. Dilor Nidan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dilor Nidan|TRUE|2900 State St|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|FALSE|suggestions|||||2023-01-22
Disak Domel|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Famir Nidan has switched 1.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Famir Nidan is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Famir Nidan|TRUE|2101 N Waterman Ave|NEUROLOGY,VASCULAR NEUROLOGY,OPHTHALMOLOGY|FALSE|suggestions|OCREVUS|KESIMPTA|||2023-01-22
Disak Domel|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Famir Nidan has switched 2.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Famir Nidan is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Famir Nidan|TRUE|2101 N Waterman Ave|NEUROLOGY,VASCULAR NEUROLOGY,OPHTHALMOLOGY|FALSE|suggestions|OCREVUS|KESIMPTA|||2023-01-18
Disak Domel|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in March, is/are not known to be on Ocrevus, and is/are associated with JIM ALLEN JAMES. Please evaluate using your own judgement and consider reaching out to JIM ALLEN JAMES.Dr. Disat Samir is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Disat Samir|TRUE|2700 Se Stratus Ave|CLINICAL NEUROPHYSIOLOGY,NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-22
Disak Domel|VISIT|Missing|Medium|Low|This HCP is believed to have written a prescription for VUMERITY in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Famir Nidan is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Famir Nidan|TRUE|2101 N Waterman Ave|NEUROLOGY,VASCULAR NEUROLOGY,OPHTHALMOLOGY|FALSE|suggestions|||VUMERITY||2023-01-17
Milor Hamir|SEND|Decline|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions||||KESIMPTA|2023-01-27
Milor Hamir|SEND|Decline|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|FALSE|Global|NEUROLOGY|FALSE|suggestions||||KESIMPTA|2023-01-30
Milor Hamir|SEND|Hold|High|Low|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|FALSE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-16
Milor Hamir|SEND|Hold|High|Medium|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|FALSE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-20
Milor Hamir|SEND|Hold|High|Medium|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|TRUE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-22
Milor Hamir|SEND|Hold|Medium|Low|This HCP is believed to have written multiple prescriptions for OCREVUS in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Lovem Firek is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Lovem Firek|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions||||OCREVUS|2023-01-22
Milor Hamir|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-22
Milor Hamir|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|FALSE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||MAVENCLAD|2023-01-28
Milor Hamir|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||MAVENCLAD|2023-01-30
Milor Hamir|SEND|Increase|Medium|Low|Our data indicates that Samim Badan has MS diagnosed patients at SAINT JOSEPHS HOSPITAL AND MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Samim Badan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Samim Badan|TRUE|240 W Thomas Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-30
Milor Hamir|SEND|Increase|Medium|Low|Our data indicates that Savel Nison has MS diagnosed patients at SAINT JOSEPHS HOSPITAL AND MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Savel Nison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Savel Nison|FALSE|340 S Willard St|NEUROLOGY|FALSE|suggestions|||||2023-01-30
Milor Hamir|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|FALSE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-21
Milor Hamir|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-20
Milor Hamir|SEND|Missing|Medium|Low|Our data indicates that Mimar Lenos has MS diagnosed patients at CENTER FOR NEUROSCIENCES that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Mimar Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimar Lenos|FALSE|Global|NEUROLOGY|TRUE|suggestions|||||2023-01-19
Milor Hamir|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Tulor Samir has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|FALSE|Global|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Milor Hamir|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Tulor Samir has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|TRUE|Global|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-29
Milor Hamir|VISIT|Decline|Medium|Low|Our data indicates that Remal Kodan has MS diagnosed patients at EL PASO NEUROLOGICAL INSTITUTE that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Remal Kodan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Remal Kodan|FALSE|Global|GENERAL PRACTICE|FALSE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Hold|Medium|Low|This HCP is believed to have written multiple prescriptions for OCREVUS in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Lovem Firek is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Lovem Firek|FALSE|Po Box 245023|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions||||OCREVUS|2023-01-20
Milor Hamir|VISIT|Hold|Medium|Low|This HCP is believed to have written multiple prescriptions for OCREVUS in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Lovem Firek is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Lovem Firek|TRUE|Po Box 245023|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions||||OCREVUS|2023-01-22
Milor Hamir|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Kadok Savak has switched 1.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Kadok Savak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kadok Savak|FALSE|13400 E Shea Blvd|NEUROLOGY|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-16
Milor Hamir|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tukik Doson has switched 1.0 patients from ZEPOSIA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tukik Doson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tukik Doson|FALSE|9590 E Ironwood Square Dr|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|TRUE|suggestions|ZEPOSIA|OCREVUS|||2023-01-30
Milor Hamir|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tusal Havak has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tusal Havak is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Tusal Havak|FALSE|710 W Bell Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Milor Hamir|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tusal Havak has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tusal Havak is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Tusal Havak|TRUE|710 W Bell Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-27
Milor Hamir|VISIT|Increase|Medium|Low|Our data indicates that Savel Nison has MS diagnosed patients at SAINT JOSEPHS HOSPITAL AND MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Savel Nison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Savel Nison|TRUE|340 S Willard St|NEUROLOGY|FALSE|suggestions|||||2023-01-30
Milor Hamir|VISIT|Increase|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with JULIUS RAY CHARLIE. Please evaluate using your own judgement and consider reaching out to JULIUS RAY CHARLIE.Dr. Ditas Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Ditas Konos|FALSE|3308 N Higley Rd|NEUROLOGY,PSYCHIATRY|FALSE|suggestions|||||2023-01-29
Milor Hamir|VISIT|Increase|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with JULIUS RAY CHARLIE. Please evaluate using your own judgement and consider reaching out to JULIUS RAY CHARLIE.Dr. Ditas Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Ditas Konos|TRUE|3308 N Higley Rd|NEUROLOGY,PSYCHIATRY|FALSE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Katas Nivak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Katas Nivak|FALSE|4273 Montgomery Blvd Ne|NEUROLOGY,EMERGENCY MEDICINE,RADIATION ONCOLOGY|TRUE|suggestions|||KESIMPTA||2023-01-28
Milor Hamir|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Katas Nivak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Katas Nivak|TRUE|4273 Montgomery Blvd Ne|NEUROLOGY,EMERGENCY MEDICINE,RADIATION ONCOLOGY|TRUE|suggestions|||KESIMPTA||2023-01-21
Milor Hamir|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for OCREVUS in (September) for the first time in 2 years. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|FALSE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions|||OCREVUS||2023-01-16
Milor Hamir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Tudot Hamir has switched 1.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tudot Hamir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudot Hamir|TRUE|6320 W Union Hills Dr|NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-19
Milor Hamir|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Tudot Hamir has switched 2.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tudot Hamir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudot Hamir|FALSE|6320 W Union Hills Dr|NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-18
Milor Hamir|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|FALSE|Global|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-29
Milor Hamir|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|TRUE|Global|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Milor Hamir|VISIT|Missing|High|Low|Our data indicates that Lores Sason has MS diagnosed patients at INTEGRATED MEDICAL SERVICES NEUROLOGY that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Lores Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Lores Sason|TRUE|14001 N 7th St|NEUROLOGY|FALSE|suggestions|||||2023-01-19
Milor Hamir|VISIT|Missing|High|Low|Our data indicates that Mimar Lenos has MS diagnosed patients at CENTER FOR NEUROSCIENCES that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Mimar Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimar Lenos|TRUE|2450 E River Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-19
Milor Hamir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with BRIAN LEP RABIN. Please evaluate using your own judgement and consider reaching out to BRIAN LEP RABIN.Dr. Fanam Turek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fanam Turek|TRUE|2201 W Fairview St|NEUROLOGY,NEUROLOGICAL SURGERY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with ERIC JOSEPH FOLTZ. Please evaluate using your own judgement and consider reaching out to ERIC JOSEPH FOLTZ.Dr. Famit Tunos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Famit Tunos|FALSE|2940 N Litchfield Rd|NEUROLOGY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with ERIC JOSEPH FOLTZ. Please evaluate using your own judgement and consider reaching out to ERIC JOSEPH FOLTZ.Dr. Famit Tunos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Famit Tunos|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in July, is/are not known to be on Ocrevus, and is/are associated with ERIC JOSEPH FOLTZ. Please evaluate using your own judgement and consider reaching out to ERIC JOSEPH FOLTZ.Dr. Famit Tunos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Famit Tunos|TRUE|2940 N Litchfield Rd|NEUROLOGY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-20
Milor Hamir|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in May, is/are not known to be on Ocrevus, and is/are associated with ISLAM MUSTAFA ABUJUBARA. Please evaluate using your own judgement and consider reaching out to ISLAM MUSTAFA ABUJUBARA.Dr. Lores Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Lores Sason|TRUE|14001 N 7th St|NEUROLOGY|FALSE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|FALSE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions||||KESIMPTA|2023-01-22
Milor Hamir|VISIT|Missing|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|TRUE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions||||KESIMPTA|2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Dinar Kovak has switched 1.0 patients from VUMERITY to OCREVUS.Consider a follow-up action based on your discretion.Dr. Dinar Kovak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dinar Kovak|FALSE|726 N Greenfield Rd|NEUROLOGY|TRUE|suggestions|VUMERITY|OCREVUS|||2023-01-19
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Dinar Kovak has switched 2.0 patients from VUMERITY to OCREVUS.Consider a follow-up action based on your discretion.Dr. Dinar Kovak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dinar Kovak|FALSE|726 N Greenfield Rd|NEUROLOGY|TRUE|suggestions|VUMERITY|OCREVUS|||2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Kadok Savak has switched 2.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Kadok Savak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kadok Savak|FALSE|Global|NEUROLOGY|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Lovem Firek has switched 1.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Lovem Firek is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Lovem Firek|FALSE|Po Box 245023|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-19
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Lovem Firek has switched 2.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Lovem Firek is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Lovem Firek|FALSE|Po Box 245023|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Mimin Ledan has switched 1.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|FALSE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|AUBAGIO|OCREVUS|||2023-01-19
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Mimin Ledan has switched 2.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|FALSE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|AUBAGIO|OCREVUS|||2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Mimin Ledan has switched 1.0 patients from MAVENCLAD to OCREVUS.Consider a follow-up action based on your discretion.Dr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|TRUE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|MAVENCLAD|OCREVUS|||2023-01-29
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Mimin Ledan has switched 1.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|TRUE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|OCREVUS|KESIMPTA|||2023-01-20
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-27
Milor Hamir|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|TRUE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-20
Milor Hamir|VISIT|Missing|Medium|Low|Our data indicates that Dilom Batek has MS diagnosed patients at HONORHEALTH NEUROLOGY that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Dilom Batek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dilom Batek|FALSE|7242 E Osborn Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-30
Milor Hamir|VISIT|Missing|Medium|Low|Our data indicates that Mimin Ledan has MS diagnosed patients at SAINT JOSEPHS HOSPITAL AND MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|TRUE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with JULIUS RAY CHARLIE. Please evaluate using your own judgement and consider reaching out to JULIUS RAY CHARLIE.Dr. Ditas Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Ditas Konos|FALSE|3308 N Higley Rd|NEUROLOGY,PSYCHIATRY|FALSE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with JULIUS RAY CHARLIE. Please evaluate using your own judgement and consider reaching out to JULIUS RAY CHARLIE.Dr. Ditas Konos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Ditas Konos|TRUE|3308 N Higley Rd|NEUROLOGY,PSYCHIATRY|FALSE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in October, is/are not known to be on Ocrevus, and is/are associated with MICHAEL VINCENT ROBERS. Please evaluate using your own judgement and consider reaching out to MICHAEL VINCENT ROBERS.Dr. Samim Badan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Samim Badan|FALSE|240 W Thomas Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-18
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in October, is/are not known to be on Ocrevus, and is/are associated with MICHAEL VINCENT ROBERS. Please evaluate using your own judgement and consider reaching out to MICHAEL VINCENT ROBERS.Dr. Samim Badan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Samim Badan|TRUE|240 W Thomas Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in September, is/are not known to be on Ocrevus, and is/are associated with LLOYD RODERICK ANDERSON. Please evaluate using your own judgement and consider reaching out to LLOYD RODERICK ANDERSON.Dr. Nesar Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Nesar Sason|FALSE|350 N Wilmot Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-19
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 1 patient(s) who visited Ocreuvs.com in September, is/are not known to be on Ocrevus, and is/are associated with LLOYD RODERICK ANDERSON. Please evaluate using your own judgement and consider reaching out to LLOYD RODERICK ANDERSON.Dr. Nesar Sason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Nesar Sason|TRUE|350 N Wilmot Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-22
Milor Hamir|VISIT|Missing|Medium|Low|There was/were 2 patient(s) who visited Ocreuvs.com in September, is/are not known to be on Ocrevus, and is/are associated with AIMEE PASQUA BORAZANCI. Please evaluate using your own judgement and consider reaching out to AIMEE PASQUA BORAZANCI.Dr. Mimin Ledan is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimin Ledan|TRUE|240 W Thomas Rd|NEUROLOGY|TRUE|suggestions|||||2023-01-21
Milor Hamir|VISIT|Missing|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Dimas Bavak is a(n) Tyler. N/A|Dimas Bavak|FALSE|4530 E Muirwood Dr|GENERAL PRACTICE|FALSE|suggestions|||KESIMPTA||2023-01-30
Nekik Kotek|SEND|Decline|High|Low|Our data indicates that Tures Tuvak has MS diagnosed patients at THE NEUROMEDICAL CENTER REHABILITATION HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Tures Tuvak is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Tures Tuvak|FALSE|Global|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-27
Nekik Kotek|SEND|Increase|Medium|Low|Our data indicates that Kamil Bason has MS diagnosed patients at RENOWN REGIONAL MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Kamil Bason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kamil Bason|FALSE|Global|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-17
Nekik Kotek|SEND|Increase|Medium|Low|Our data indicates that Sanak Kodan has MS diagnosed patients at ROCKY MOUNTAIN MULTIPLE SCLEROSIS CLINIC that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Sanak Kodan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Sanak Kodan|FALSE|Global|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-27
Nekik Kotek|SEND|Increase|Medium|Low|Our data indicates that Zakit Fison has MS diagnosed patients at CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|FALSE|Global|NEUROLOGY|FALSE|suggestions|||||2023-01-27
Nekik Kotek|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|FALSE|Global|NEUROLOGY|FALSE|suggestions||||MAVENCLAD|2023-01-29
Nekik Kotek|VISIT|Decline|High|Low|Our data indicates that Tures Tuvak has MS diagnosed patients at THE NEUROMEDICAL CENTER REHABILITATION HOSPITAL that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Tures Tuvak is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Tures Tuvak|TRUE|370 E 9th Ave|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|||||2023-01-27
Nekik Kotek|VISIT|Decline|Medium|Low|For the three months ending in (September, 2023), Savel Fitek has switched 1.0 patients from OCREVUS to BRIUMVI.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Savel Fitek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Savel Fitek|TRUE|370 E 9th Ave|NEUROLOGY|TRUE|suggestions|OCREVUS|BRIUMVI|||2023-01-16
Nekik Kotek|VISIT|Increase|High|Low|For the three months ending in (September, 2023), Zakit Fison has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions|OCREVUS|MAVENCLAD|||2023-01-16
Nekik Kotek|VISIT|Increase|High|Low|For the three months ending in (September, 2023), Zakit Fison has switched 1.0 patients from OCREVUS to TYSABRI.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions|OCREVUS|TYSABRI|||2023-01-17
Nekik Kotek|VISIT|Increase|High|Low|Our data indicates that Kamil Bason has MS diagnosed patients at RENOWN REGIONAL MEDICAL CENTER that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Kamil Bason is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kamil Bason|TRUE|85 Kirman Ave|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-17
Nekik Kotek|VISIT|Increase|High|Low|Our data indicates that Sanak Kodan has MS diagnosed patients at ROCKY MOUNTAIN MULTIPLE SCLEROSIS CLINIC that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Sanak Kodan is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Sanak Kodan|TRUE|370 E 9th Ave|NEUROLOGY,FAMILY MEDICINE|TRUE|suggestions|||||2023-01-27
Nekik Kotek|VISIT|Increase|High|Low|Our data indicates that Zakit Fison has MS diagnosed patients at CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions|||||2023-01-27
Nekik Kotek|VISIT|Increase|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in August, is/are not known to be on Ocrevus, and is/are associated with CARRIE MICHELLE HERSH. Please evaluate using your own judgement and consider reaching out to CARRIE MICHELLE HERSH.Dr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions|||||2023-01-29
Nekik Kotek|VISIT|Increase|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Lodok Sanos is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Lodok Sanos|TRUE|10381 Double R Blvd|FAMILY MEDICINE,NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-27
Nekik Kotek|VISIT|Increase|High|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Zakit Fison is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Zakit Fison|TRUE|888 W Bonneville Ave|NEUROLOGY|FALSE|suggestions||||MAVENCLAD|2023-01-30
Nekik Kotek|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Saver Samel has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Saver Samel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Saver Samel|FALSE|9280 W Sunset Rd|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-27
Nekik Kotek|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Saver Samel has switched 1.0 patients from OCREVUS to MAVENCLAD.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Saver Samel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Saver Samel|TRUE|9280 W Sunset Rd|NEUROLOGY,INTERNAL MEDICINE|TRUE|suggestions|OCREVUS|MAVENCLAD|||2023-01-29
Nekik Kotek|VISIT|Missing|High|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Tudos Hamel is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudos Hamel|TRUE|2500 Wigwam Pkwy|NEUROLOGY|TRUE|suggestions|||KESIMPTA||2023-01-16
Nekik Kotek|VISIT|Missing|Medium|Low|Our data indicates that Kasam Finos has MS diagnosed patients at SAINT ROSE DOMINICAN HOSPITALS ROSE DE LIMA CAMPUS that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Kasam Finos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Kasam Finos|FALSE|1621 E Flamingo Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-16
Nekik Kotek|VISIT|Missing|Medium|Low|Our data indicates that Kasam Finos has MS diagnosed patients at SAINT ROSE DOMINICAN HOSPITALS ROSE DE LIMA CAMPUS that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Kasam Finos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Kasam Finos|TRUE|1621 E Flamingo Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-17
Nenar Domel|SEND|Decline|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions||||KESIMPTA|2023-01-30
Nenar Domel|SEND|Hold|High|Low|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|TRUE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-16
Nenar Domel|SEND|Hold|High|Medium|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|FALSE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-22
Nenar Domel|SEND|Hold|High|Medium|Our data indicates that Redor Letek has MS diagnosed patients at BANNER UNIVERSITY MEDICAL CENTER PHOENIX that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Redor Letek is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Redor Letek|TRUE|13640 N 99th Ave|NEUROLOGY|TRUE|suggestions|||||2023-01-20
Nenar Domel|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|FALSE|Global|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-22
Nenar Domel|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|FALSE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||MAVENCLAD|2023-01-30
Nenar Domel|SEND|Increase|High|Low|This HCP is believed to have written multiple prescriptions for MAVENCLAD in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||MAVENCLAD|2023-01-28
Nenar Domel|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|FALSE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-20
Nenar Domel|SEND|Increase|Medium|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions||||KESIMPTA|2023-01-21
Nenar Domel|SEND|Missing|Medium|Low|Our data indicates that Mimar Lenos has MS diagnosed patients at CENTER FOR NEUROSCIENCES that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Mimar Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimar Lenos|FALSE|Global|NEUROLOGY|TRUE|suggestions|||||2023-01-19
Nenar Domel|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Tulor Samir has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-29
Nenar Domel|VISIT|Decline|High|Low|For the three months ending in (September, 2023), Tulor Samir has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tulor Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tulor Samir|TRUE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Nenar Domel|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Kadok Savak has switched 1.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Kadok Savak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kadok Savak|TRUE|13400 E Shea Blvd|NEUROLOGY|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-16
Nenar Domel|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tukik Doson has switched 1.0 patients from ZEPOSIA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tukik Doson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tukik Doson|FALSE|9590 E Ironwood Square Dr|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|TRUE|suggestions|ZEPOSIA|OCREVUS|||2023-01-30
Nenar Domel|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tukik Doson has switched 1.0 patients from ZEPOSIA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tukik Doson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tukik Doson|TRUE|9590 E Ironwood Square Dr|NEUROLOGY,CLINICAL NEUROPHYSIOLOGY|TRUE|suggestions|ZEPOSIA|OCREVUS|||2023-01-22
Nenar Domel|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tusal Havak has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tusal Havak is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Tusal Havak|FALSE|710 W Bell Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-27
Nenar Domel|VISIT|Increase|Medium|Low|For the three months ending in (September, 2023), Tusal Havak has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tusal Havak is a(n) Henry. Henry (the HET-Hesitant HCP) is less sophisticated in his understanding of MS and is most likely a community-based, non-MS specialist who treats a multitude of neurologic conditions. Henry is not comfortable starting his patients on a HET, and may not be fully aware of Ocrevuss clinical and safety profile.|Tusal Havak|TRUE|710 W Bell Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Nenar Domel|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Katas Nivak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Katas Nivak|TRUE|4273 Montgomery Blvd Ne|NEUROLOGY,EMERGENCY MEDICINE,RADIATION ONCOLOGY|TRUE|suggestions|||KESIMPTA||2023-01-28
Nenar Domel|VISIT|Increase|Medium|Low|This HCP is believed to have written a prescription for OCREVUS in (September) for the first time in 2 years. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|FALSE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions|||OCREVUS||2023-01-16
Nenar Domel|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Dimit Samir has switched 1.0 patients from OCREVUS to KESIMPTA.Consider a follow-up action based on your discretion. For example:1. Connect with your FRM to discuss any access issues.Alternatively directly reach out to the HCP to understand the reason for the switch, and whether they are considering switching additional patients away from OCREVUS2. Sending a Veeva Approved Email3. Scheduling a callDr. Dimit Samir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dimit Samir|TRUE|4400 N 32nd St|NEUROLOGY|TRUE|suggestions|OCREVUS|KESIMPTA|||2023-01-21
Nenar Domel|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Tudot Hamir has switched 1.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tudot Hamir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudot Hamir|FALSE|Global|NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-19
Nenar Domel|VISIT|Missing|High|Low|For the three months ending in (October, 2023), Tudot Hamir has switched 2.0 patients from AUBAGIO to OCREVUS.Consider a follow-up action based on your discretion.Dr. Tudot Hamir is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Tudot Hamir|FALSE|Global|NEUROLOGY|FALSE|suggestions|AUBAGIO|OCREVUS|||2023-01-18
Nenar Domel|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-30
Nenar Domel|VISIT|Missing|High|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|TRUE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-29
Nenar Domel|VISIT|Missing|High|Low|Our data indicates that Mimar Lenos has MS diagnosed patients at CENTER FOR NEUROSCIENCES that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Mimar Lenos is a(n) Missy. Missy (the MS Specialist) often uses a HET-first approach for her patients, but perceives clinical parity (safety & efficacy) across all aCD20 options - it will be difficult to convince her otherwise. Missy may be open to using other aCD20s if they are seen to offer reduced time-to-therapy, reduced staff burden, and/or alleviate financial pressures|Mimar Lenos|FALSE|Global|NEUROLOGY|TRUE|suggestions|||||2023-01-19
Nenar Domel|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with BRIAN LEP RABIN. Please evaluate using your own judgement and consider reaching out to BRIAN LEP RABIN.Dr. Fanam Turek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fanam Turek|FALSE|2201 W Fairview St|NEUROLOGY,NEUROLOGICAL SURGERY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-21
Nenar Domel|VISIT|Missing|High|Low|There was/were 1 patient(s) who visited Ocreuvs.com in April, is/are not known to be on Ocrevus, and is/are associated with BRIAN LEP RABIN. Please evaluate using your own judgement and consider reaching out to BRIAN LEP RABIN.Dr. Fanam Turek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Fanam Turek|TRUE|2201 W Fairview St|NEUROLOGY,NEUROLOGICAL SURGERY,INTERNAL MEDICINE|FALSE|suggestions|||||2023-01-22
Nenar Domel|VISIT|Missing|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|FALSE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions||||KESIMPTA|2023-01-18
Nenar Domel|VISIT|Missing|High|Low|This HCP is believed to have written multiple prescriptions for KESIMPTA in the recent 12 months after a hiatus of not writing this product in the previous 12 months. Consider a follow-up action based on your discretion.3. Inviting the HCP to a speaker bureau programDr. Kanas Tuson is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kanas Tuson|TRUE|14420 W Meeker Blvd|NEUROLOGY,PSYCHIATRY,PAIN MEDICINE (PSYCHIATRY)|FALSE|suggestions||||KESIMPTA|2023-01-20
Nenar Domel|VISIT|Missing|Medium|Low|For the three months ending in (October, 2023), Kadok Savak has switched 2.0 patients from GILENYA to OCREVUS.Consider a follow-up action based on your discretion.Dr. Kadok Savak is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Kadok Savak|TRUE|13400 E Shea Blvd|NEUROLOGY|TRUE|suggestions|GILENYA|OCREVUS|||2023-01-18
Nenar Domel|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|FALSE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-20
Nenar Domel|VISIT|Missing|Medium|Low|For the three months ending in (September, 2023), Zadon Sanos has switched 1.0 patients from TYSABRI to OCREVUS.Consider a follow-up action based on your discretion.Dr. Zadon Sanos is a(n) Amelia. Amelia (the Almost aCD20 Believer) remains most comfortable with an escalation approach and most often prescribes orals for her MS patients. This is exacerbated by her lack of convenient access to infusion capabilities. She has typically reserved non-oral HETs for patients with high disease burden or breakthrough disease.|Zadon Sanos|TRUE|3507 S Mercy Rd|NEUROLOGY|FALSE|suggestions|TYSABRI|OCREVUS|||2023-01-27
Nenar Domel|VISIT|Missing|Medium|Low|Our data indicates that Dilom Batek has MS diagnosed patients at HONORHEALTH NEUROLOGY that we believe may begin a DMT in the next two to three months. We predict that this physician is treating the following number of DMT eligible 1L MS patient(s):1L DMT Predicted Patients: 1.0Dr. Dilom Batek is a(n) Debby. Debby (the Dabbler) recognizes Ocrevus as a powerful first-line option for patients with higher disease burden, but remains wary of broader use due to perceived safety tradeoffs. Debby likely views orals as efficacious in their own right, and believes she is adequately addressing the disease with these DMTs for most patients. She often allows patients to be the tie-breaker among a group of therapies.|Dilom Batek|TRUE|7242 E Osborn Rd|NEUROLOGY|FALSE|suggestions|||||2023-01-30
Nenar Domel|VISIT|Missing|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Dimas Bavak is a(n) Tyler. N/A|Dimas Bavak|FALSE|4530 E Muirwood Dr|GENERAL PRACTICE|FALSE|suggestions|||KESIMPTA||2023-01-28
Nenar Domel|VISIT|Missing|Medium|Low|This HCP is believed to have written a prescription for KESIMPTA in (September) for the first time in 2 years. Consider a follow-up action based on your discretion. (review competitive objection handler)3. Inviting the HCP to a speaker bureau programDr. Dimas Bavak is a(n) Tyler. N/A|Dimas Bavak|TRUE|4530 E Muirwood Dr|GENERAL PRACTICE|FALSE|suggestions|||KESIMPTA||2023-01-29
